Table 1. Classification of cell-associated vesicles.
Classification | Origin | Mechanism of release | Size | Potential markers | Source* |
---|---|---|---|---|---|
Extracellular vesicles | Mixed population of exosomes, microvesicles, apoptotic bodies, large oncosomes | Fusion of MVBs and direct budding from the plasma membrane | Variable 40 nm–10 µm |
Varied: tetraspanins, major histocompatibility complex (MHC) molecules, cytosolic proteins | [13] |
Intraluminal vesicles | Multiple cell types (endosome-associated) |
Intraluminal vesicles exist within MVBs and upon release these vesicles are termed exosomes | 40–100 nm | MHC II, tetraspanins, ubiquitinated proteins | [1] [16] |
Ectosomes | Multiple cell types (commonly neutrophils or monocytes) | Plasma membrane budding | 100–350 nm | TyA, C1q | [21] |
Exosomes | Multiple cell types (endosome-associated) | Fusion of MVBs with plasma membrane | 40–100 nm | CD9, CD63, CD81, TSG101, Alix, Hsp70 | [1] [15] |
Exomeres | Multiple cell types | Not yet described | <50 nm | Non-membranous, Hsp90-β | [5] |
Prostasomes | Prostate epithelium | Budding from the plasma membrane of prostate epithelial cells | 40–130 nm | PAP, PSA, TMPRSS2, PSCA | [20] |
Microvesicles | Multiple cell types | Plasma membrane budding | 100–1000 nm | Phosphatidylserine, integrins, selectin, CD40 | [17] [18] |
Oncosomes/ large oncosomes |
Tumour cells | Cancer cell membrane budding | 1–10 µm | EGFRvIII, ARF6, Cav-1, CK18, oncogenic material | [107] [14] [23] [14] |
Apoptotic bodies | Cells undergoing apoptosis | Blebbing and fragmentation of the plasma membrane of apoptotic cells | 500–4000 nm | Phosphatidylserine, annexin V, thrombospondin, C3b | [19] |
Enveloped virus particles | Virally infected cells | Plasma membrane budding | ~100 nm | Viral-encoded proteins | [22] |
*The cited references are not an exhaustive list. We apologize to authors whose work was unintentionally omitted.